66220-315 : Vibativ 15 mg/mg Intravenous Injection, Powder, Lyophilized, for Solution


NDC: 66220-315
Labeler: Cumberland Pharmaceuticals Inc.
Product Type: Human Prescription Drug
Drug Name:  Vibativ
Dosage Form: Intravenous Injection, Powder, Lyophilized, for Solution
Application #: NDA022110
Rev. Date: 


NDC Package Codes:

  • 66220-315-11: 1 VIAL IN 1 CARTON (66220‑315‑11) > 15 MG IN 1 VIAL
  • 66220-315-22: 12 VIAL IN 1 CASE (66220‑315‑22) > 15 MG IN 1 VIAL
  • 66220-315-44: 4 VIAL, SINGLE‑DOSE IN 1 CARTON (66220‑315‑44) / 50 ML IN 1 VIAL, SINGLE‑DOSE

Active Ingredients:

  • Telavancin Hydrochloride

Dosage Strength:

  • 15 mg/mg

Pharmaceutical Classes:

  • Lipoglycopeptide Antibacterial [EPC]
  • Lipoglycopeptides [EXT]

Related Products:

Based on records with the same trade name.
  • 0469-3525 Vibativ 250 mg/1 Intravenous Injection, Powder, Lyophilized, for Solution by Astellas Pharma Us Inc.
  • 0469-3575 Vibativ 750 mg/1 Intravenous Injection, Powder, Lyophilized, for Solution by Astellas Pharma Us Inc.
  • 52118-001 Vibativ 15 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Theravance, Inc.
  • 52118-002 Vibativ 15 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Theravance, Inc.
  • 62847-001 Vibativ 15 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Theravance Biopharma Antibiotics, Inc.
  • 62847-002 Vibativ 15 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Theravance Biopharma Antibiotics, Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 66220-315 QR Code

< Prev: 66220-287Next: 66220-422 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.